Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulinastatin for sepsis-related organ failure in children
ISRCTN15982148Phase 3Active, not recruiting
- Sponsor
- Guangdong Techpool Bio-pharma
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ulinastatin in sepsis (2 arms), sponsored by Guangdong Techpool Bio-pharma. Primary endpoint: Composite outcome of 28-day mortality and/or presence of at least one organ failure on day 7 after randomization. Started Oct 2024; status: active, not recruiting.
02
Drugs
ulinastatin
03
Conditions
sepsis
Beyond the preview
Go deeper on ISRCTN15982148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15982148.